Business
-
AstraZeneca has announced a partnership with Honeywell for development of lower global warming potential MDIs using HFO-1234ze as a propellant. The company said that Breztri budesonide/ glycopyrronium/ formoterol fumarate is the first product it plans… Read more . . .
-
Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Columbia has acquired exclusive rights to commercialize AstraZeneca’s Pulmicort Respules budesonide inhalation suspension for the treatment of asthma in Columbia. AstraZeneca will manufacture the inhalation suspension and… Read more . . .
-
Glenmark Pharmaceuticals and SaNOtize have announced the approval of FabiSpray nitric oxide nasal spray (NONS) for the treatment of COVID-19 by the Drugs Controller General of India (DCGI) and the launch of the nasal spray… Read more . . .
-
Third Pole Therapeutics announced that it has raised an additional $25 million in a financing round led by existing investors for continued development of its tankless inhaled nitric oxide (iNO) systems. The company also said… Read more . . .
-
Ethris GmbH said that it has closed a $26.3 million Series B financing round led by Laureus Capital, with proceeds earmarked for continued development of the company’s ETH47 and ETH42 inhaled mRNA based therapies, which… Read more . . .
-
Aridis Pharmaceuticals announced that it has received an award of $1.9 million from the Bill & Melinda Gates Foundation to fund preclinical development of inhaled monoclonal antibodies against influenza and SARS-CoV-2. Aridis is developing both… Read more . . .
-
Intranasal vaccine developer Leyden Laboratories has closed a $140M Series B financing led by Casdin Capital and GV, the company said. Proceeds will go toward development of the company’s pipeline, which includes its PanFlu intranasal… Read more . . .
-
Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene
According to Opiant Pharmaceuticals, the company’s contract with the Biomedical Advanced Research and Development Authority (BARDA) has been amended to provide an additional $2.2 million to support activities related to a 505(b)(2) NDA submission for OPNT003 nalmefene… Read more . . .
-
Aculys Pharma has acquired development and commercialization rights to Neurelis’s Valtoco diazepam nasal spray in Japan, Australia, and other Asia-Pacific countries, including New Zealand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, South Korea, Thailand and… Read more . . .
-
Glenmark Pharmaceuticals announced that Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, has acquired the rights to commercialize Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray in Singapore, Hong Kong and Vietnam. Lotus will make… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden